文献速递头颈部肿瘤放疗

利用基因组调整辐射剂量(GARD)个体化鼻咽癌放射治疗剂量

Using the genomic adjusted radiation dose (GARD) to personalize the radiation dose in nasopharyngeal cancer.
PubMed 文献 · Radiother Oncol · 2024-04-16

基于一项随机III期试验(NPC-0501)中92例III–IVB期鼻咽癌患者,评估基因组调整辐射剂量(GARD)与局部区域控制的关系。尽管处方物理剂量均一(中位70 Gy,范围66–76 Gy),GARD值分布广泛(中位50.7,范围31.1–67.8)。多变量分析显示GARD阈值45与局部区域无失败率独立相关(p=0.008),GARD或可作为鼻咽癌个体化放疗剂量的框架。

要点

  • 92例III–IVB期鼻咽癌患者接受同步放化疗联合(新)辅助化疗,中位物理剂量70 Gy(范围66–76 Gy)。
  • GARD值分布广泛(中位50.7,范围31.1–67.8),GARD阈值45与局部区域无失败率独立相关(p=0.008)。
  • 按达到GARD阈值所需物理剂量(RxRSI)可分为三组:<66 Gy组59例(64.1%)、66–74 Gy组20例(21.7%)、>74 Gy组13例(14.1%)。

核心结论

  • GARD与接受放疗的鼻咽癌患者的局部区域控制独立相关,GARD可能是鼻咽癌个体化放疗剂量的潜在框架。

研究设计与样本

  • 研究纳入一项随机III期试验(NPC-0501,NCT00379262)中92例美国癌症联合委员会/国际抗癌联盟III期至IVB期鼻咽癌患者。
  • 患者接受同步放化疗联合(新)辅助化疗,主要终点为局部区域无失败率(LRFFR)。

主要发现

  • 处方物理剂量均一(中位70 Gy,范围66–76 Gy),但GARD值分布广泛(中位50.7,范围31.1–67.8)。
  • 多变量分析中,GARD阈值(GARDT)45与LRFFR独立相关(p=0.008)。
  • 按达到GARDT所需物理剂量(RxRSI)分组:放射敏感肿瘤RxRSI<66 Gy组59例(64.1%),中度放射敏感肿瘤RxRSI在66–74 Gy组20例(21.7%),放射抗拒肿瘤需>74 Gy组13例(14.1%)。

关键数值与推荐

  • GARD阈值45与局部区域无失败率独立相关(p=0.008)。
  • 达到GARD阈值45所需物理剂量(RxRSI)<66 Gy者59例(64.1%),66–74 Gy者20例(21.7%),>74 Gy者13例(14.1%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Locally advanced nasopharyngeal cancer (NPC) patients undergoing radiotherapy are at risk of treatment failure, particularly locoregional recurrence. To optimize the individual radiation dose, we hypothesize that the genomic adjusted radiation dose (GARD) can be used to correlate with locoregional control. METHODS: A total of 92 patients with American Joint Committee on Cancer / International Union Against Cancer stage III to stage IVB recruited in a randomized phase III trial were assessed (NPC-0501) (NCT00379262). Patients were treated with concurrent chemo-radiotherapy plus (neo) adjuvant chemotherapy. The primary endpoint is locoregional failure free rate (LRFFR). RESULTS: Despite the homogenous physical radiation dose prescribed (Median: 70 Gy, range 66-76 Gy), there was a wide range of GARD values (median: 50.7, range 31.1-67.8) in this cohort. In multivariable analysis, a GARD threshold (GARDT) of 45 was independently associated with LRFFR (p = 0.008). By evaluating the physical dose required to achieve the GARDT (RxRSI), three distinct clinical subgroups were identified: (1) radiosensitive tumors that RxRSI at dose < 66 Gy (N = 59, 64.1 %) (b) moderately radiosensitive tumors that RxRSI dose within the current standard of care range (66-74 Gy) (N = 20, 21.7 %), (c) radioresistant tumors that need a significant dose escalation above the current standard of care (>74 Gy) (N = 13, 14.1 %). CONCLUSION: GARD is independently associated with locoregional control in radiotherapy-treated NPC patients from a Phase 3 clinical trial. GARD may be a potential framework to personalize radiotherapy dose for NPC patients.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Chiang CL, Chan KSK, Li H, et al. Using the genomic adjusted radiation dose (GARD) to personalize the radiation dose in nasopharyngeal cancer. Radiother Oncol. 2024. PMID: 38636709. doi:10.1016/j.radonc.2024.110287

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。